Actively Recruiting
Phase 2 Study of Intravenous Cefepime-Enmetazobactam in Children from Birth to Under 18 Hospitalized with Complicated Urinary Tract Infection
Led by Orchid Pharma Europe GmbH · Updated on 2026-08-20
40
Participants Needed
8
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the pharmacokinetics, safety, and tolerability of a fixed dose combination of two drugs, cefepime and enmetazobactam, given intravenously to children from birth up to less than 18 years old who are hospitalized with complicated urinary tract infections cUTI. This phase 2 study supports regulatory requirements in the US and Europe to extend cefepime-enmetazobactam use to pediatric patients with cUTI. Participants receive cefepime and enmetazobactam together as a fixed dose combination administered intravenously over two hours every 8 hours. Treatment lasts between 3 and 7 days, depending on how quickly infection symptoms resolve. Participants remain hospitalized during treatment and have follow-up visits 7 and 14 days after treatment ends, with a final study visit conducted by phone or in person 28 days after treatment completion. Throughout the study, participants undergo blood tests to measure drug levels and monitoring for safety and tolerability from before the first dose until 28 days after treatment. Researchers assess infection symptoms and collect urine cultures. Follow-up visits ensure recovery and evaluate treatment effects. The total participation time spans about a month from treatment start to final follow-up.
CONDITIONS
Brief Title
A Study to Investigate PK, Safety, Tolerability of Cefepime-enmetazobactam in Pediatric Participants With cUTI
Research Team
P
patrick velicitat, MD
D
Divya Kashyap, BDS
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here